Savient Pharmaceuticals Inc Quick Ratio (SVNT) starting from the third quarter 2013 to third quarter 2012, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Savient Pharmaceuticals Inc  (SVNT)

Savient Pharmaceuticals Inc's Quick Ratio

SVNT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Savient Pharmaceuticals Inc's Cash & cash equivalent, this led to improvement in Savient Pharmaceuticals Inc's Quick Ratio to 4.26, Quick Ratio remained below Savient Pharmaceuticals Inc average.

Within Biotechnology & Pharmaceuticals industry 26 other companies have achieved higher Quick Ratio than Savient Pharmaceuticals Inc in third quarter 2013. While Quick Ratio total ranking has improved so far during the Q3 2013 to 569, from total ranking in the second quarter 2013 at 998.

Explain Quick Ratio?
How much Cash & cash equivalents SVNT´s has?
What are SVNT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SVNT Quick Ratio (Sep 30 2013)
Q3		 (Jun 30 2013)
Q2		 (Mar 31 2013)
Q1		 (Dec 31 2012)
Q4		 (Sep 30 2012)
Q3
Y / Y Current Liabilities Change -74.03 % -17.06 % -64.72 % -4.6 % 56.23 %
Y / Y Cash & cash equivalent Change -70.21 % -63.8 % -47.48 % -43.29 % -25.52 %
Quick Ratio MRQ 4.26 2.08 8.05 3.36 3.71
SVNT's Total Ranking # 569 # 998 # 1015 # 1014 #
Seq. Current Liabilities Change -67.19 % 189.97 % -70.21 % -8.38 % 4.78 %
Seq. Cash & cash equivalent Change -32.73 % -25.17 % -28.55 % -17.17 % -18.26 %



Quick Ratio third quarter 2013 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 27
Healthcare Sector # 166
Overall Market # 569


Quick Ratio Statistics
High Average Low
13.9 5.35 1.27
(Mar 31 2011)   (Sep 30 2010)




Financial Statements
Savient Pharmaceuticals Inc's Current Liabilities $ 8 Millions Visit SVNT's Balance sheet
Savient Pharmaceuticals Inc's Cash & cash equivalent $ 35 Millions Visit SVNT's Balance sheet
Source of SVNT's Sales Visit SVNT's Sales by Geography


Cumulative Savient Pharmaceuticals Inc's Quick Ratio

SVNT's Quick Ratio for the trailling 12 Months

SVNT Quick Ratio

 (Sep 30 2013)
12 Months		 (Jun 30 2013)
12 Months		 (Mar 31 2013)
12 Months		 (Dec 31 2012)
12 Months		 (Sep 30 2012)
12 Months
Y / Y Current Liabilities TTM Growth -39.26 % -10.45 % -5.56 % 14.93 % 41.69 %
Y / Y Cash & cash equivalent TTM Growth -55.09 % -44.45 % -35.52 % -38.81 % -18.82 %
Quick Ratio TTM 3.58 3.57 4.3 4.26 4.84
Total Ranking TTM # 1098 # 164 # 947 # 929 #
Seq. Current Liabilities TTM Growth -24.84 % -5.18 % -13.74 % -1.2 % 10.81 %
Seq. Cash & cash equivalent TTM Growth -24.53 % -21.42 % -12.8 % -13.14 % -6.65 %

Quick ratio ranking by company, industry and sector >> Back to SVNT Financial Strength Comparisons >> Go to Compare SVNT Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Savient Pharmaceuticals Inc's average Cash & cash equivalent, this led to increase in in Savient Pharmaceuticals Inc's Quick Ratio to 3.58, above SVNT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 24 other companies have achieved higher Quick Ratio than Savient Pharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2013 from 164 to 1098.

Explain Quick Ratio?
How much Cash & cash equivalents SVNT´s has?
What are SVNT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 25
Healthcare Sector # 109
Within the Market # 1098


trailing twelve months Quick Ratio Statistics
High Average Low
4.47 3.52 2.59
(Sep 30 2012)   (Mar 31 2012)




Companies with similar Quick Ratio in the quarter ending Sep 30 2013, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2013 MRQ Cash & cash equivalentSep 30 2013 MRQ Current Liabilities
Fresh Tracks Therapeutics Inc   11.32 $ 58.966  Millions$ 5.210  Millions
Chelsea Therapeutics International, Ltd.  11.25 $ 20.882  Millions$ 1.857  Millions
Curis Inc   11.06 $ 63.231  Millions$ 5.718  Millions
Novavax inc   10.27 $ 146.410  Millions$ 14.260  Millions
Bio techne Corp  9.11 $ 184.699  Millions$ 20.276  Millions
Viskase Holdings inc   8.72 $ 21.691  Millions$ 2.487  Millions
Bluebird Bio Inc   8.19 $ 216.791  Millions$ 26.484  Millions
China Biologic Products Holdings Inc   8.02 $ 135.105  Millions$ 16.852  Millions
Aevi Genomic Medicine, Inc.  7.47 $ 26.791  Millions$ 3.588  Millions
Repligen Corp  7.17 $ 62.991  Millions$ 8.784  Millions
Acceleron Pharma inc  7.10 $ 117.392  Millions$ 16.523  Millions
Receptos, Inc.  7.10 $ 80.781  Millions$ 11.378  Millions
Compugen Ltd  6.65 $ 51.485  Millions$ 7.739  Millions
Vaxart Inc   5.24 $ 60.800  Millions$ 11.600  Millions
Cyclo Therapeutics Inc   4.66 $ 0.540  Millions$ 0.116  Millions
Amgen Inc   4.66 $ 22,558.000  Millions$ 4,843.000  Millions
Pluri Inc   4.43 $ 25.372  Millions$ 5.731  Millions
Savient Pharmaceuticals Inc  4.26 $ 34.624  Millions$ 8.130  Millions
Sorrento Therapeutics Inc   4.26 $ 6.430  Millions$ 1.510  Millions
Seagen Inc   3.75 $ 373.848  Millions$ 99.637  Millions
Exelixis Inc   3.74 $ 291.430  Millions$ 77.880  Millions
Brainstorm Cell Therapeutics inc   3.69 $ 5.115  Millions$ 1.386  Millions
Protalix Biotherapeutics inc   3.62 $ 91.397  Millions$ 25.226  Millions
Nanostring Technologies Inc   3.37 $ 52.214  Millions$ 15.488  Millions
Acorda Therapeutics Inc   3.31 $ 292.445  Millions$ 88.258  Millions
Biocryst Pharmaceuticals Inc   3.24 $ 42.741  Millions$ 13.182  Millions
Palisade Bio Inc   3.19 $ 16.402  Millions$ 5.148  Millions
Agenus Inc  3.13 $ 30.205  Millions$ 9.653  Millions
Viropharma Inc  3.00 $ 275.194  Millions$ 91.787  Millions
Telik Inc  2.55 $ 3.197  Millions$ 1.255  Millions

Date modified: 2026-09-02T17:38:16+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.